Canada OKs Solta Clear + Brilliant - Analyst Blog
September 07 2011 - 9:54AM
Zacks
Solta Medical (SLTM), a provider of aesthetic
laser treatments, has secured the approval of Health Canada for
marketing its Clear + Brilliant laser aesthetic treatment in the
North American nation. The device was approved in the U.S. and
Europe in May 2011 and is already gaining notable traction in these
markets.
The novel Clear + Brilliant laser treatment is based on
fractional laser technology for treating and preventing aging of
the skin. The treatment is targeted at young patients seeking to
control the signs of aging. It will enable physicians and
skin care providers to address the unmet customer needs
and expand
their patient base. Clear + Brilliant is targeted for patients who
are not satisfied with over the counter or spa treatments but not
ready yet for a more aggressive laser skin resurfacing
treatment.
California-based Solta Medical develops and markets devices for
aesthetic applications and is a global leader in the medical
aesthetics market. Its leading brands for skin tightening and skin
resurfacing are Thermage (a non-invasive radiofrequency procedure
for tightening and contouring the skin) and Fraxel (a novel class
of skin rejuvenation therapy).
Solta acquired aesthetic devices maker Aesthera Corporation in
March 2010. The acquisition brought the Isolaz brand of products
for treating acne.
Solta derives its revenues primarily from the sale of its
systems, treatment tips and other consumables. The company’s sales
fell roughly 3.7% year over year to $28.95 million in
second-quarter fiscal 2011.
Revenues from its treatment tips and consumables went up 10%
with growth registered in every region across the globe. Moreover,
new system sales of Fraxel Dual and Thermage CPT systems expanded
at a double-digit clip in the quarter.
The U.S. market for aesthetic procedures to treat skin is
growing at a healthy pace, thanks to an aging baby boomer
population, availability of a broad range of safe and effective
treatments and ongoing transition from invasive to
minimally-invasive or non-invasive procedures. Solta competes with
Allergan Inc. (AGN), Syneron
Medical (ELOS), Cutera (CUTR) and
Palomar Medical Technologies (PMTI).
ALLERGAN INC (AGN): Free Stock Analysis Report
CUTERA INC (CUTR): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
PALOMAR MED TEC (PMTI): Free Stock Analysis Report
SOLTA MEDICAL (SLTM): Free Stock Analysis Report
Zacks Investment Research
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Sep 2023 to Sep 2024